Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

Slides:

Advertisements

Similar presentations

Name the type of tissue.. Name type of tissue.

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

CD25 expression is associated with unfavorable clinical outcome.

An endothelial metronome breast cancer?

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Cancer makes new friends with old tricks

Is NF-κB2/p100 a direct activator of programmed cell death?

PARPi combinations against HR-proficient tumors.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

TIE2hi/VEGFAhi TEMs are present in the TMEM

Macrophages and Therapeutic Resistance in Cancer

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Figure 3 The yin and yang of tumour-associated

Macrophages and Therapeutic Resistance in Cancer

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Epigenetic regulation of miR-193b in liposarcomagenesis.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,

Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.

NICD1 immunohistochemical staining in normal and tumor tissue.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Figure 5. Tissue uptake of circulating 125I-β2-m.

Sterile Inflammation Fuels Gastric Cancer

Figure 1 CD52 expression on innate myeloid and lymphoid cell subsets

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Identification of a ufo1 Candidate Gene from the Mapping Region.

PTENP1 sensitizes renal cancer cells to chemotherapy.

Dietary plant extracts inhibit NF-κB activation in vitro.

Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.

coTCRcys-transduced T cells control tumor growth in vivo.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Matriptase-2 inhibited breast tumor development in vivo.

M-Wnt and E-Wnt cells cluster tightly with claudin-low and basal-like breast tumors, respectively, by microarray analysis. M-Wnt and E-Wnt cells cluster.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Expression pattern of TLR-4 and MyD88 in EOC cells.

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Comparison of variant associations from previous reports and results from the KP GWAS meta-analysis for 105 known prostate cancer risk SNPs. Plotted values.

A macrophage-tumor cell cross-talk within Amppos tumors.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Isolation and proteomic profiling of TEX

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Establishment of transcriptional class distinction in melanocytes.

Change in FES uptake in the tumor during fulvestrant treatment.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

DHT-dependent phase of prostate cancer.

Survival, subsequent therapies, and response.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Leukocyte populations in normal and neoplastic breast tissues.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

CD36 expression in tissue adjacent and distal to the tumor.

CD8+ depletion and IFN-γ–deficient myeloid cells and lung metastasis inhibition in Tgfbr2MyeKO mice. CD8+ depletion and IFN-γ–deficient myeloid cells and.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Genotype-specific combinatorial drug sensitivities in melanoma.

Presentation transcript:

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Dark and light gray areas denote tumor and tumor stromal tissues, respectively. The outer unshaded area indicates the circulation. Tumor stromal macrophages (M) and circulating neutrophils (N) are recruited to tumor tissues (T) depending on the cell type in which NF-κB activation is inhibited and the mode of tumor cell death. Thomas Enzler et al. Cancer Discovery 2011;1:496-507 ©2011 by American Association for Cancer Research